| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Abemaciclib |
08.03.04.01 |
Formulary
|
NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abemaciclib |
08.03.04.01 |
Formulary
|
NICE TA 579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA 387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Abraxane® |
08.01.05 |
Formulary
|
NICE TA 476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA146: Psoriasis - adalimumab |
| Adalimumab |
13.05.03 |
Formulary
|
NICE TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
13.05.03 |
Formulary
|
TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40) |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA146: Adalimumab for the treatment of adults with psoriasis |
| Adefovir Dipivoxil |
05.03.03.01 |
Non Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Adefovir Dipivoxil |
05.03.03.01 |
Non Formulary
|
NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib |
| Aflibercept |
08.01.05 |
Formulary
|
NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept |
08.01.05 |
Formulary
|
NICE TA 305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept |
08.01.05 |
Formulary
|
NICE TA 294: Aflibercept solution for injection for treating wet age‑related macular degeneration |
| Aflibercept |
08.01.05 |
Formulary
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
| Aflibercept |
08.01.05 |
Formulary
|
NICE TA 486: Aflibercept for treating choroidal neovascularisation |
| Aflibercept |
08.01.05 |
Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA294: Macular degeneration (wet age-related) - aflibercept |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 486: Aflibercept for treating choroidal neovascularisation |
| Alectinib |
08.01.05 |
Formulary
|
NICE TA 536: Alectinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA 312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA177: Eczema (chronic) - alitretinoin |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Anastrozole |
08.03.04.01 |
Formulary
|
NG101: Early and locally advanced breast cancer: diagnosis and management |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Non Formulary
|
NICE TA156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245: Venous thromboembolism - apixaban (hip and knee surgery |
| Apremilast |
10.01.03 |
Formulary
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA433 Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419 Apremilist for treating moderate to severe plaque psoriasis. |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA 526: Arsenic trioxide for treating acute promyelocytic leukaemia |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA 525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Atezolizumab |
08.01.05 |
Formulary
|
NICE TA639:Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Avelumab |
08.01.05 |
Formulary
|
Avelumab for treating metastatic Merkel cell carcinoma (TA517) |
| Axicabtagene ciloleucel |
08.01.05 |
Formulary
|
NICE TA 559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA 399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Azathioprine |
10.01.03 |
Formulary
|
NICE TA 480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Baricitinib |
10.01.03 |
Formulary
|
NICE TA 466: Baricitinib for moderate to severe rheumatoid arthritis |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA 481: Immunosuppressive therapy for kidney transplant in adults |
| Belimumab |
10.01.03 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
| Benralizumab |
03.04.02 |
Formulary
|
NICE TA 565: Benralizumab for treating severe eosinophilic asthma |
| Bevacizumab |
16.01 |
Formulary
|
NICE TA 285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer |
| Bevacizumab |
16.01 |
Formulary
|
NICE TA 214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer |
| Bevacizumab |
16.01 |
Formulary
|
NICE TA 242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pa |
| Bevacizumab |
16.01 |
Formulary
|
NICE TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer |
| Bevacizumab |
16.01 |
Formulary
|
NICE TA 263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer |
| Bevacizumab |
16.01 |
Formulary
|
NICE TA 284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bevacizumab |
16.01 |
Formulary
|
NICE TA 212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer |
| Bevacizumab |
16.01 |
Formulary
|
NICE TA 178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA263: Breast cancer with capecitabine |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA212: Colorectal cancer (metastatic) - bevacizumab |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA214: Breast Cancer with taxane |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA 178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE CG94: Unstable angina and NSTEMI |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA 589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Blinatumomab |
08.02 |
Formulary
|
NICE TA 450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Boceprevir |
05.03.03.02 |
Non Formulary
|
NICE TA253: Hepatitis C (genotype 1) - boceprevir |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Multiple myeloma - bortezomib (induction therapy |
| Bosutinib |
08.01.05 |
Formulary
|
NICE TA 401: Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum Toxin Type A |
04.07.04.02 |
Non Formulary
|
NICE TA260: Botox for migraine prophylaxis |
| Botulinum Toxin Type A |
04.09.03 |
Formulary
|
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA 577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA 524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brigatinib |
08.01.05 |
Formulary
|
NICE TA 570: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brodalumab ▼ |
13.05.03 |
Formulary
|
NICE TA511 Brodalumab for treating moderate to severe plaque psoriasis |
| Burosumab |
06.06.02 |
Formulary
|
NICE HST 8: Burosumab for treating X-linked hypophosphataemia in children and young people |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA 391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes |
| Cannabidiol |
04.06 |
Formulary
|
NICE TA615 |
| Cannabidiol |
04.06 |
Formulary
|
NICE TA614 |
| Cannabis extract |
10.02.02 |
Formulary
|
NICE NG144: Cannabis-based medicinal products |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA60: Colorectal cancer - capecitabine and tegafur uracil |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA 212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA 457: Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Cemiplimab |
08.02.04 |
Formulary
|
NICE TA 592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA 500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA 395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Certolizumab pegol |
13.05.03 |
Formulary
|
NICE TA 574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Certolizumab Pegol |
13.05.03 |
Formulary
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
TA 439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Head and neck cancer (squamous cell carcinoma) - cetuximab |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA323 Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
| Ciclosporin |
11.99.99.99 |
Non Formulary
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Ciprofloxacin |
12.01.01 |
Formulary
|
BNF advice for ciprofloxacin use in the ear |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA616 |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Colistimethate inhaler |
05.01.07 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase (Clostridium histolyticum) |
10.03.01 |
Non Formulary
|
NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA 406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA 422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Cubitan |
A2.03.02 |
Non Formulary
|
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157: Venous thromboembolism - dabigatran |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Daclatasvir |
05.03.03.02 |
Non Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Dacomitinib |
08.01.05 |
Formulary
|
NICE TA 595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA 597: Dapagliflozin with insulin for treating type 1 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Daratumumab |
08.01.05 |
Formulary
|
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510)14.3.18 |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA 573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Daunorubicin/ cytarabine |
08.01.03 |
Formulary
|
NICE TA 552: Liposomal cytarabine - daunorubicin for untreated acute myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270) |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA 404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women |
| Denosumab |
06.06.02 |
Non Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA 303: Teriflunomide for treating relapsing–remitting multiple sclerosis |
| Dinutuximab beta |
08.02.04 |
Formulary
|
NICE TA 538: Dinutuximab beta for treating neuroblastoma |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Doxorubicin Hydrochloride |
08.01.02 |
Formulary
|
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA 197 |
| Dupilumab |
13.05.01 |
Formulary
|
NICE TA 534 Dupilumab for treating moderate to severe atopic dermatitis |
| Dupilumab▼ |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Durvalumab |
08.02.04 |
Formulary
|
NICE TA 578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) |
| Eluxadoline |
01.04.02 |
Formulary
|
NICE TA 471 Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336 : Empagliflozin in combination therapy for treating type 2 diabetes |
| Encorafenib |
08.01.05 |
Formulary
|
NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Eplerenone |
02.02.03 |
Formulary
|
Chronic Heart Failure in adults |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
| Epoetin Zeta |
09.01.03 |
Formulary
|
NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA 423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA 583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Etanercept |
10.01.03 |
Formulary
|
TA103 - For the treatment of adults with psoriasis |
| Etanercept |
10.01.03 |
Formulary
|
TA 195 - For the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Formulary
|
TA 373 - For the treatment of juvenile idiopathic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
TA 383 - For the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
TA 199 - For the treatment of psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
TA 375 - For the treatment of rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA199 Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA455 Adalimumab, etanercept and usterkinumab for treating plaque psoriasis in childen and young people |
| Etanercept |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Etanercept |
13.01 |
Formulary
|
NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis |
| Etanercept |
13.01 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
13.01 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
13.01 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Etanercept |
13.01 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Etanercept |
13.01 |
Formulary
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Etelcalcitide |
09.05.01.02 |
Formulary
|
NICE TA 448: Etelcalcetide for treating secondary hyperparathyroidism |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA 432: Everolimus for advanced renal cell carcinoma after previous treatment |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA 421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exemestane |
08.03.04.01 |
Formulary
|
NG101:Early and locally advanced breast cancer: diagnosis and management |
| Exenatide prolonged release |
06.01.02.03 |
Non Formulary
|
NICE NG28: Type 2 diabetes in adults: management |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Hypercholesterolaemia - ezetimibe |
| Febuxostat |
10.01.04 |
Formulary
|
Febuxostat for the management of hyperuricaemia in people with gout (TA164) |
| Febuxostat |
10.01.04 |
Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
| Finasteride |
06.04.02 |
Formulary
|
NICE CG97: Lower urinary tract symptoms: quick reference guide |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA 254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis |
| Fludarabine |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
| Fludarabine |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271) |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA 374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE NG85: Pancreatic cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Gemtuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA 545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA 527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glencaprevir-pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA 499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220: Psoriatic arthritis - golimumab |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA225: Rheumatoid arthritis - golimumab |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA 497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy |
| Guselkumab▼ |
13.05.03 |
Formulary
|
NICETA521 Guselkumab for treating moderate to severe plaque psoriasis |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA70: Leukaemia (chronic myeloid) - imatinib |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after failure of conventional therapy |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohn's disease - infliximab (review) and adalimumab (review of TA40) |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA134: Infliximab for the treatment of adults with psoriasis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
| Inotersen |
06.07 |
Formulary
|
NICE Highly specialised technologies guidance [HST9]: Inotersen for treating hereditary transthyretin amyloidosis |
| Inotuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Insulin |
06.01.01.01 |
Non Formulary
|
Nice web site |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA267: Chronic heart failure - ivabradine |
| Ixazomib |
08.01.05 |
Formulary
|
NICE TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ixekizumab |
10.01.03 |
Formulary
|
NICE TA 537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab |
13.05.03 |
Formulary
|
NICE TA442 Ixekizumab for treating moderate tosever plaque psoriasis |
| Larotrectinib |
08.01.05 |
Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA171: Multiple myeloma - lenalidomide |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA 551: Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Letermovir |
05.03 |
Formulary
|
NICE TA 591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Letrozole |
08.03.04.01 |
Formulary
|
NG101: Early and locally advanced breast cancer: diagnosis and management |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE:NG28 Type 2 diabetes in adults: management |
| Lorlatinib |
08.01.05 |
Formulary
|
NICE TA 628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Lubiprostone |
01.06.07 |
Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Mannitol |
03.07 |
Formulary
|
For treating cystic fibrosis |
| Mannitol inhalation |
03.07 |
Non Formulary
|
NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266) |
| Mepolizumab |
03.04.02 |
Formulary
|
NICE TA 431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Methenamine Hippurate |
05.01.13 |
Formulary
|
BNF advice for the prescribing of methenamine hippurate |
| Methoxy Polyethylene Glycol-Epoetin Beta |
09.01.03 |
Formulary
|
NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE:CG186 Multiple sclerosis: Multiple sclerosis in adults: management |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA 522 Midostaurin for untreated acute myeloid leukaemia |
| Mifamurtide |
08.02.04 |
Formulary
|
NICE TA 235: Mifamurtide for the treatment of osteosarcoma |
| Mifamurtide |
08.02.04 |
Non Formulary
|
NICE TA154: Hepatitis B - telbivudine |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Mycophenolate Mofetil |
08.02.01 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Mycophenolate Sodium |
08.02.01 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Nalmefene |
04.10.01 |
Formulary
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid‑induced constipation |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA 425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA 379: Nintedanib for treating idiopathic pulmonary fibrosis |
| Niraparib |
08.01.05 |
Formulary
|
NICE TA 528: Niraparib for maintenance treatment of relapsed, platinum sensitive ovarian, fallopian tube and peritoneal cancer |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA 400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA 417: Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA 558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA 581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Nusinersen |
10.02 |
Formulary
|
NICE TA 588: Nusinersen for treating spinal muscular atrophy |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA 443: Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
| Obinutuzumab |
08.02.03 |
Formulary
|
Obinutuzumab for untreated advanced follicular lymphoma (TA513 ) 21.3.18 |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA 533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA 585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Ocriplasmin |
11.08.02 |
Formulary
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
| Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
| Ofatumumab |
08.02.03 |
Non Formulary
|
NICE TA202: Chronic lymphocytic leukaemia - ofatumumab |
| Olaparib |
20 |
Non Formulary
|
NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA 598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Pablociclib |
08.01.05 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA55: Ovarian cancer - paclitaxel (review) |
| Paclitaxel |
08.01.05 |
Formulary
|
Early and TA101: locally advanced breast cancer: diagnosis and management |
| Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA 495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA 380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Patiromer calcium |
09.02.01.01 |
Formulary
|
NICE TA623: Patiromer for treating hyperkalaemia |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib |
| Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE TA155: guidance on pegaptanib in AMD (August 2008) |
| Pegasparagase |
08.01 |
Formulary
|
NICE TA 408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA 96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA 200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA 106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA 300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Peginterferon alfa-2a |
08.02.04 |
Formulary
|
NICE TA 75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon beta-1a |
08.02.04 |
Formulary
|
NICE TA624:Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 531: Pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 522 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer where cisplatin is unsuitable |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA 402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA124: Lung cancer (non-small-cell) - pemetrexed |
| Pentosan polysulphate sodium |
07.04.03 |
Formulary
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
| Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA 509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA 569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pirfenidone |
03.11 |
Formulary
|
NICE TA 504: Pirfenidone for treating idiopathic pulmonary fibrosis |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA 427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Ponatinib |
08.01.05 |
Formulary
|
NICE TA 451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (review of technology appraisal guidance 182) |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211 Constipation (women) Prucalopride |
| Radium-223 dichloride |
08.01.05 |
Formulary
|
NICE TA 412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Raloxifene Hydrochloride |
06.04.01.01 |
Non Formulary
|
NICE TA160: quick reference guide on osteoporosis |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA274: Macular oedema (diabetic) - ranibizumab |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA 555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Reslizumab |
03.04.02 |
Formulary
|
NICE TA 479: Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Non Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Ribociclib |
08.03.04.01 |
Formulary
|
NICE TA 593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Rifaximin |
05.01.07 |
Non Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA 596: Risankizumab for treating moderate to severe plaque psoriasis |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA243: Follicular lymphoma - rituximab (review) |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for treatment of DVT |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for AF |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607 |
| Roflumilast |
03.03.03 |
Formulary
|
NICE TA 461 - Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Rucaparib |
08.01.05 |
Formulary
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril and valsartan |
02.05.05 |
Formulary
|
NICE TA388 |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA 485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
13.05.03 |
Formulary
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
| Secukinumab |
10.01.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C |
| Sipuleucel- T |
20 |
Non Formulary
|
NICE TA332: Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer |
| Sirolimus |
08.02.02 |
Formulary
|
NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people |
| Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA 599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir/velpatasvir/voxilaprevir |
05.03.03.02 |
Formulary
|
NICE TA 507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review) |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) - human growth hormone |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA 474: Sorafenib for treating advanced hepatocellular carcinoma |
| Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA178: Renal cell carcinoma |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tadalafil |
07.04.05 |
Formulary
|
NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273) |
| Talimogene laherparepvec |
08.01.05 |
Formulary
|
NICE TA 410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Hepatitis C (genotype 1) - telaprevir |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Brain cancer - temozolomide |
| Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA173 |
| Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for relapsing remitting MS |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA 228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA 575: Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
| Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA 554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
| Tobramycin inhaler |
05.01.04 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Tocilizumab |
10.01.03 |
Formulary
|
Tocilizumab for treating giant cell arteritis (TA518) 18.4.18 |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA247: Rheumatoid arthritis - tocilizumab (rapid review TA198) |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA 480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA 547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA 543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA 396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA101: Early and locally advanced breast cancer: diagnosis and management |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA235: Osteosarcoma - mifamurtide |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
| Trifluridine and tipiracil |
08.01.05 |
Formulary
|
NICE TA 405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA 456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
| Ustenkinumab |
10.01.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustenkinumab |
10.01.03 |
Formulary
|
NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA 342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA 352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Vortioxetine |
04.03.03 |
Formulary
|
NICE TA367: Vortioxetine for treating major depressive episodes |
| Zolpidem |
04.01.01 |
Non Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
